• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Category: Audio

  • Genomically Targeted Therapy Delays Advanced Breast Cancer Progression
    • in AJO · Audio · Oncology
    • — 31 Oct, 2018

    Genomically Targeted Therapy Delays Advanced Breast Cancer Progression

     

     

    MUNICH—A combination of the phosphoinositide 3-kinase (PI3K) inhibitor alpelisib plus fulvestrant significantly extended progression free survival (PFS) compared to placebo plus fulvestrant in patients with hormone receptor positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) advanced breast …

    Read more
    Palbociclib Combination Prolongs Life After Breast Cancer Hormone Therapy
    • in Audio
    • — 29 Oct, 2018

    Palbociclib Combination Prolongs Life After Breast Cancer Hormone Therapy

    MUNICH—Patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer who were treated with a combination of the cyclin dependent kinase (CDK) 4/6 inhibitor palbociclib in combination with fulvestrantlived longer than those receiving a placebo …

    Read more
  • Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer
    • in AJO · Audio · Oncology
    • — 27 Oct, 2018

    Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer

    MUNICH—More than four years median overall survival was reported in patients treated with an inhibitor of anaplastic lymphoma kinase (ALK) for their ALK gene rearranged non-small cell lung cancer (NSCLC) in a single-arm phase two study reported at the 2018 …

    Read more
    Pembrolizumab: No Survival Gains Second Line In Gastric Cancer
    • in Audio · AJO · Oncology
    • — 18 Oct, 2018

    Pembrolizumab: No Survival Gains Second Line In Gastric Cancer

    Reporter: Sarah Maxwell

    BARCELONA—Pembrolizumab did not significantly improve overall survival (OS) or progression free survival (PFS) compared with paclitaxel as second-line therapy in patients with advanced gastric or gastro-esophageal junction cancer that had progressed after one line of chemotherapy (containing …

    Read more
  • Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib
    • in Audio · AJO · Oncology
    • — 15 Oct, 2018

    Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib

    BARCELONA—Oral cabozantinib “significantly improved” overall survival (OS) and progression free survival (PFS) compared to placebo in patients with advanced hepatocellular carcinoma(HCC) whose disease had progressed despite sorafenib therapy in the phase 3 CELESTIAL trial reported to the 2018 ESMO World …

    Read more
    Trifluridine with Tipiracil Lifts Survival in Refractory Gastric Cancer
    • in Audio · AJO · Oncology
    • — 11 Oct, 2018

    Trifluridine with Tipiracil Lifts Survival in Refractory Gastric Cancer

    BARCELONA—A chemotherapy combination consisting of trifluridine with tipiracil showed a “clinically meaningful and statistically significant” improvement in overall survival (OS) and progression free survival (PFS) compared with placebo in patients with heavily-pretreated metastatic gastric cancer (mGC) refractory to standard therapies …

    Read more
  • Esophageal Cancer Prevented By Proton Pump Inhibitor Plus Aspirin
    • in AJO · ASCO · Audio · Oncology
    • — 15 Aug, 2018

    Esophageal Cancer Prevented By Proton Pump Inhibitor Plus Aspirin

    CHICAGO—A 25 per cent risk reduction for esophageal cancer was found to be associated with prophylactic therapy consisting of a proton pump inhibitor (PPI) and aspirin in the phase three randomized ASPECT multicenter study from the United Kingdom reported at …

    Read more
    Preoperative Chemoradiotherapy Extends Survival in Pancreatic Cancer
    • in AJO · Audio · Oncology
    • — 25 Jul, 2018

    Preoperative Chemoradiotherapy Extends Survival in Pancreatic Cancer

    CHICAGO—Patients with resectable and “borderline resectable” pancreatic cancers treated with chemoradiation before surgery (followed by adjuvant chemotherapy) had significantly improved outcomes compared to those randomized to have surgery first and adjuvant chemotherapy in the Dutch Pancreatic Cancer Group’sPREOPANC-1 randomized, controlled, …

    Read more
  • Can Initial Radiotherapy Improve Survival with Prostate Cancer?
    • in AJO · Audio · Oncology
    • — 20 Jul, 2018

    Can Initial Radiotherapy Improve Survival with Prostate Cancer?

    CHICAGO—Patients with newly-diagnosed hormone-sensitive metastatic prostate cancer (mPC) who had prostate radiotherapy (RT) before their androgen deprivation therapy (ADT) lived longer than those treated with standard ADT alone in a retrospective analysis—the largest single-center experience to date of primary tumor-directed …

    Read more
    Whole Genome Sampling Identifies Targetable Prostate Cancer Subgoups
    • in Audio
    • — 20 Jul, 2018

    Whole Genome Sampling Identifies Targetable Prostate Cancer Subgoups

    CHICAGO—Clinically targetable mutations were identified and patient subgroups pinpointed by whole genome sampling (WGS) of castration-resistant metastatic prostate cancer (mPC) in a study reportedatthe 2018 Annual Meeting of the American Society of Clinical Oncology. (https://meetinglibrary.asco.org/record/160671/abstract)

    Lisanne F van …

    Read more
  • Test Spares Extended Endocrine Therapy In Low-Risk ER+ Breast Cancer
    • in AJO · Audio · Oncology
    • — 18 Jul, 2018

    Test Spares Extended Endocrine Therapy In Low-Risk ER+ Breast Cancer

    CHICAGO—A gene test that predicts for relapse in women with estrogen receptor positive early breast cancer can identify patients with low-risk disease who could safely avoid extending their endocrine therapy beyond the standard five years, according to study findings reported …

    Read more
    Conservative Breast Therapy Better for Men
    • in AJO · Audio · Oncology
    • — 13 Jul, 2018

    Superior Survival in Conservatively Treated Male Breast Cancer

    CHICAGO—Men who had breast-conserving therapy (BCT) including radiation for their early breast cancer lived longer than those who had total or partial mastectomy—with or without radiation—in findings from a large retrospective survey of male breast cancer reported at the 2018 …

    Read more
  • « Previous Page
  • Next Page »
  • Sign up for AudioMedica.com news

    * = required field
    Speciality




  • Home
  • Category: Audio

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.